Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand

Overview

• Theratechnologies Q2 revenue of $17.7 mln beats analyst expectations, per LSEG data

• Net loss for Q2 was $4.46 mln, missing analyst estimates, per LSEG data

• Co entered definitive agreement to be acquired by Future Pak affiliate

Outlook

• Theratechnologies withdraws Fiscal 2025 revenue and EBITDA guidance, due to Future Pak deal

• Company plans to launch EGRIFTA WR, improved version of medication for HIV in Q3 2025.

• Theratechnologies sees strong demand for EGRIFTA SV and Trogarzo.

• Company anticipates growth contingent on reimbursement and supply chain.

Result Drivers

• SUPPLY DISRUPTION - EGRIFTA SV sales declined due to supply disruption, impacting revenue negatively

• STRONG DEMAND - Record high patient enrollments for EGRIFTA SV indicate strong demand, per CEO Paul Lévesque

• TROGARZO SALES - Increased Trogarzo sales driven by higher unit sales and selling prices

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Theratechnologies Inc is C$5.53, about 22.2% above its July 8 closing price of C$4.30

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNX21pNVj